ライフサイエンスコーパス: radiotherapy

1 tected lesions (surgery or stereotactic body radiotherapy).

2 monitoring treatment response; and targeting radiotherapy.

3 nssphenoidal surgery, medical therapies, and radiotherapy.

4 during contemporary conformal breast cancer radiotherapy.

5 d chemoradiotherapy than in patients who had radiotherapy.

6 survive standard therapies-chemotherapy and radiotherapy.

7 NSCLC delivering conventionally fractionated radiotherapy.

8 erapy and can limit the duration and dose of radiotherapy.

9 tumors regress at similar rates after plaque radiotherapy.

10 partial-breast]) compared with whole-breast radiotherapy.

11 ving anti-CCR2 antibody treatment to improve radiotherapy.

12 s to their limited sensitivity to chemo- and radiotherapy.

13 targeting enhances the anti-tumor effects of radiotherapy.

14 lopment of more sophisticated strategies for radiotherapy.

15 h to prevent hair loss from chemotherapy and radiotherapy.

16 ansarterial radioembolization, ablation, and radiotherapy.

17 of LC patients received preoperative planned radiotherapy.

18 , using less chemotherapy and more selective radiotherapy.

19 red with standard FU and LV before and after radiotherapy.

20 b combined with neoadjuvant capecitabine and radiotherapy.

21 ; 0.9 MBq/kg) at least 2 wk after completing radiotherapy.

22 tic drugs for synergistically combined chemo-radiotherapy.

23 c therapy, helical tomotherapy, and adaptive radiotherapy.

24 ting personalized radiobiological effects in radiotherapy.

25 stimate the radiobiological effect of clinic radiotherapy.

26 ed surgery, and 16.6% of those who underwent radiotherapy.

27 c strategy to improve the response of GBM to radiotherapy.

28 of the cytotoxic effects of temozolomide and radiotherapy.

29 q22.1-q22.2 amplification fail to respond to radiotherapy.

30 32 patients previously treated with radical radiotherapy.

31 n ions are an increasingly important tool in radiotherapy.

32 tered before, rather than concurrently with, radiotherapy.

33 ned to chemoradiotherapy and 109 patients to radiotherapy.

34 ction could be an alternative to whole-brain radiotherapy.

35 lute long-term risks of modern breast cancer radiotherapy.

36 h are resistant to standard chemotherapy and radiotherapy.

37 d to conventional and 83 to hypofractionated radiotherapy.

38 personalisation and biological adaptation of radiotherapy.

39 as higher in women who had received adjuvant radiotherapy.

40 f excision or, where appropriate, chest-wall radiotherapy.

41 red with those without previous extracranial radiotherapy (0.59 [95% CI 0.36-0.96], p=0.034; median o

42 ly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs 101 [38%]; p=0.05).

43 my (36.2 [95% CI, 30.4-42.0]), external beam radiotherapy (13.9 [95% CI, 6.7-21.2]), and brachytherap

44 cal prostatectomy (41.1%), 249 external beam radiotherapy (21.8%), and 109 brachytherapy (9.6%).

45 azine chemotherapy along with involved-field radiotherapy (25 Gy) for early stage (IA, IB, and IIA) a

46 g patients who received a complete course of radiotherapy (3086 [estimated survival probability, 73.2

47 tabine (825 mg/m(2) orally twice daily) with radiotherapy (50.4 Gy in 1.8 Gy fractions daily, approxi

48 0 mg/m(2) per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions); and also d

49 using the minimisation technique, to receive radiotherapy (59.4 Gy in 33 fractions of 1.8 Gy) alone o

50 delling-could open new doors to personalised radiotherapy adaptation and treatment.

51 objective was to determine whether previous radiotherapy affected progression-free survival, overall

52 arge regional variation exists in the use of radiotherapy after breast-conserving surgery (BCS) for d

53 gn to either palliative chemoradiotherapy or radiotherapy alone for treatment of malignant dysphagia

54 A short course of radiotherapy alone should be considered a safe and well

55 , increase in dysphagia relief compared with radiotherapy alone, with minimal improvement in dysphagi

56 ined with radiation, survival gains exceeded radiotherapy alone.

57 lts of treatment of non-MALT lymphomas using radiotherapy also were good, but they were not as favora

58 t radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-do

59 rcinoma (RCC) is polyresistant to chemo- and radiotherapy and biologicals, including TNF-related apop

60 duced skin injury is a common side effect of radiotherapy and can limit the duration and dose of radi

61 icant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and

62 ntial toxicity and the confounding impact of radiotherapy and chemoradiation.

63 which correlates strongly with resistance to radiotherapy and chemotherapy across different tumors.

64 ometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7%

65 noma, and contributes to NPC's resistance to radiotherapy and cisplatin by regulating DNA damage and

66 ponse and altered immunity in the setting of radiotherapy and cisplatin treatment and to evaluate the

67 l carcinoma (HNSCC) have better responses to radiotherapy and higher overall survival rates than do p

68 urthermore, the immunosuppressive effects of radiotherapy and STING agonists can be abrogated in huma

69 s designed to show superiority of once-daily radiotherapy and was not powered to show equivalence, th

70 r predicting the absorbed doses in molecular radiotherapy and, thus, the safety and efficacy of a tre

71 Hodgkin lymphoma (HL) survivors treated with radiotherapy and/or chemotherapy are known to have incre

72 one local treatment (surgery with or without radiotherapy) and had completed 4-6 years of adjuvant en

73 ) after radical prostatectomy, external beam radiotherapy, and brachytherapy vs active surveillance.

74 (photochemothermal therapies, immunotherapy, radiotherapy, and drug delivery).

75 e advanced disease may require chemotherapy, radiotherapy, and lymph node dissection.

76 logical effects of oxaliplatin chemotherapy, radiotherapy, and photodynamic therapy.

77 ancer cells to conventional chemotherapy and radiotherapy, and the potential to overcome tumor microe

78 med for both reduced-dose and partial-breast radiotherapy, and was confirmed by the test against the

79 eatment type (radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and watchful

80 ology centres, enabled by recent advances in radiotherapy apparatus.

81 RT dosage to improve survival.Significance: Radiotherapy appears to influence systemic IDO activity

82 n exposure from nuclear incidents and cancer radiotherapy are undeniable realities.

83 logic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate cancer is s

84 inical adverse effect for patients receiving radiotherapy as part of the standard course of treatment

85 ncology modalities but also chemotherapy and radiotherapy as standards of care in the oncology clinic

86 le if patients received chemoradiotherapy or radiotherapy as the main treatment, reported LNP proport

87 ; 95% CI, 0.59-0.81; P < .001) and receiving radiotherapy at a different hospital than the one where

88 ns for BCR after prostatectomy without prior radiotherapy at a PSA level of less than 1 ng/mL.

89 A total of 122 patients (40.9%) responded to radiotherapy at day 10 and 116 patients (38.9%) at day 4

90 e for muscle-invasive bladder cancer (MIBC), radiotherapy-based, bladder-sparing trimodal therapy (TM

91 X-ray broad beam and a multiplanar microbeam radiotherapy beam.

92 are appropriate for antineoplastic agents or radiotherapy being administered.

93 ntial chemotherapy followed by postoperative radiotherapy (C-->PORT).

94 e radiotherapy technique is implementable in radiotherapy centres worldwide.

95 t therapies, thus creating a major hurdle in radiotherapy/chemotherapy.

96 tomy followed by multiagent chemotherapy and radiotherapy; cohort one included patients with R0 resec

97 gnificantly worse with altered fractionation radiotherapy compared with concomitant chemoradiotherapy

98 feriority of partial-breast and reduced-dose radiotherapy compared with the standard whole-breast rad

99 atients who previously received extracranial radiotherapy compared with those without previous extrac

100 atients who previously received extracranial radiotherapy compared with those without previous extrac

101 t total mesorectal excision 5-10 weeks after radiotherapy completion.

102 Trials including a non-conventional radiotherapy control group, investigating hypofractionat

103 signed (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy

104 diotherapy (SCRT) compared with conventional radiotherapy (ConvRT) evaluating clinically meaningful e

105 Radiotherapy de-escalation has the potential to improve

106 fter brain metastasis resection, whole brain radiotherapy decreases local recurrence, but might cause

107 here is a substantial opportunity to improve radiotherapy delivery beyond just technological and anat

108 To determine whether incomplete radiotherapy delivery is associated with worse clinical

109 ructed breast can increase the complexity of radiotherapy delivery.

110 Radiotherapy did not offer a benefit compared with chemo

111 a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with sta

112 erapy in young children and reduction of the radiotherapy dose and volume of brain irradiated.

113 A single 8-Gy radiotherapy dose for bone metastases should be offered

114 nter phase II study investigated a selective radiotherapy dose increase to tumor areas with significa

115 It was necessary for the radiotherapy dose to be as high as possible while fulfil

116 The radiotherapy dose was 35 Gy in 15 fractions over 3 weeks

117 The radiotherapy dose was not associated with DFS when adjus

118 tivity could be used to identify the optimum radiotherapy dose.

119 nosis features that could not be reversed by radiotherapy doses up to 86 Gy.

120 the TCC cohort despite assignment of uniform radiotherapy doses within disease types.

121 al was defined as avoidance of external-beam radiotherapy (EBRT) and enucleation.

122 eatment in vivo significantly enhances chemo-radiotherapy efficacy and improves survival of rats and

123 licable to GWAS data and are not specific to radiotherapy endpoints.

124 Preclinical studies have found radiotherapy enhances antitumour immune responses.

125 g-term findings showed that hypofractionated radiotherapy failed the intent of either reducing physic

126 Radiotherapy for breast cancer results in variable cardi

127 ols), who underwent contemporary (1998-2013) radiotherapy for breast cancer with computed tomography-

128 xamine whether regional practice patterns of radiotherapy for DCIS affect the use of mastectomy in th

129 Although patients who do not receive initial radiotherapy for DCIS are candidates for subsequent BCS

130 among women who had not previously received radiotherapy for DCIS.

131 Hypofractionated radiotherapy for elderly patients with fair to good perf

132 e benign or low-grade brain tumors requiring radiotherapy for long-term tumor control, SCRT compared

133 toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) befo

134 development of combinatorial treatment with radiotherapy for patients with glioblastoma.

135 fficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NS

136 l wound healing after eAPR with preoperative radiotherapy for rectal cancer was not improved when usi

137 requently occur after eAPR with preoperative radiotherapy for rectal cancer.

138 ) of 97 patients had previously received any radiotherapy for the treatment of NSCLC before the first

139 adiotherapy group and 38 (35%, 26-44) in the radiotherapy group obtained dysphagia relief (difference

140 breast group, compared with the whole-breast radiotherapy group).

141 Three (13%) patients with previous thoracic radiotherapy had treatment-related pulmonary toxicity co

142 Although radiotherapy has been used more frequently in past decad

143 r radiation sensitization, and external beam radiotherapy has emerged as a valid treatment option.

144 Radiotherapy has long been the mainstay of treatment for

145 Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision me

146 radicals, including photodynamic therapy and radiotherapy, have emerged as promising treatments in th

147 diotherapy than in patients without previous radiotherapy (hazard ratio [HR] 0.56 [95% CI 0.34-0.91],

148 red with those without previous extracranial radiotherapy (HR 0.50 [0.30-0.84], p=0.0084; median prog

149 diotherapy than in patients without previous radiotherapy (HR 0.58 [95% CI 0.36-0.94], p=0.026; media

150 g performed on cancer tissues prior to chemo/radiotherapy identified one hypermethylated CpG site (Cp

151 (VMAT), and fixed-field intensity-modulated radiotherapy (IMRT) for NSCLC delivering conventionally

152 chemotherapy and surgery, and nine (6%) had radiotherapy in addition to other therapies.

153 A subtherapeutic dose of local radiotherapy in combination with chNKG2D T-cell treatmen

154 comparing conventional and hypofractionated radiotherapy in high-risk, organ-confined prostate cance

155 for future testing in the field of targeted radiotherapy in mice.

156 ur data suggest that previous treatment with radiotherapy in patients with advanced NSCLC results in

157 ermine whether PET can obviate consolidation radiotherapy in patients with diffuse large B-cell lymph

158 ministered concurrently with curative intent radiotherapy in patients with LAHNSCC.

159 ADT) (86.0%, n = 308) alone or combined with radiotherapy in prostate cancer IS (80.8%, n = 517).

160 The Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and nec

161 rapy compared with the standard whole-breast radiotherapy in terms of local relapse in a cohort of pa

162 Inhibiting ATG4B in combination with radiotherapy in treating mice with intracranial GBM xeno

163 air the anticancer efficacy of cisplatin and radiotherapy in tumor-bearing mice.

164 rocognitive dysfunction include avoidance of radiotherapy in young children and reduction of the radi

165 nation radiotherapy vs altered fractionation radiotherapy) included 33 trials and 11 423 patients.

166 effects after reduced-dose or partial-breast radiotherapy, including two patient domains achieving st

167 th BCL-2 inhibition, as DNA damage caused by radiotherapy increases the activity of pro-apoptotic BCL

168 tment type (radical prostatectomy or radical radiotherapy), increasing comorbidity does not seem to s

169 High quality sequencing data from radiotherapy-induced cancers is particularly scarce and

170 consisted of ABVD followed by involved-node radiotherapy (INRT), regardless of ePET result.

171 cedure, with stratification by country, age, radiotherapy intent, nodal status, and oestrogen recepto

172 Radiotherapy is a rational candidate for combining with

173 Therapeutic radiotherapy is an important treatment of pelvic cancers

174 ck (MARCH) showed that altered fractionation radiotherapy is associated with improved overall and pro

175 Radiotherapy is essential to the treatment of most solid

176 city-induced hair loss from chemotherapy and radiotherapy is often encountered in cancer treatment, a

177 ariability of normal tissue damage following radiotherapy is poorly understood.

178 rst version of MARCH, that hyperfractionated radiotherapy is, along with concomitant chemoradiotherap

179 the use of upfront EGFR-TKI, and deferral of radiotherapy, is associated with inferior OS in patients

180 d cancer cell's response to chemotherapy and radiotherapy, little is known about the role of histone

181 Intensive chemo/radiotherapy may impair ongoing immune responses, while

182 After radiotherapy (n = 85), tracer sensitivity was largely PS

183 phocholine, as a scaffold for tumor-targeted radiotherapy of pediatric malignancies.

184 m that Cu-Cy nanoparticles may improve X-ray radiotherapy on cancer treatment and X-ray activated Cu-

185 nce, smoking can determine the net effect of radiotherapy on mortality, but smoking cessation substan

186 How soon after radiotherapy one can expect an improvement in QOL is unk

187 hair, receiving hospice care, and undergoing radiotherapy or chemotherapy.

188 ow or HER2-negative breast cancers following radiotherapy or endocrine therapy, and this drives tumor

189 w or HER2-negative breast cancers undergoing radiotherapy or endocrine therapy.

190 enetoclax combined with either external beam radiotherapy or radioimmunotherapy (RIT), which joins th

191 ) of injury and mitigation in patients after radiotherapy or radiological accidents.

192 lecular biomarker for cancers susceptible to radiotherapy or to DSB-inducing chemotherapy.

193 nsurance status was predictive of completing radiotherapy (OR, 1.60; 95% CI, 1.16-2.21; P = .004).

194 nhance the efficacy of cancer immunotherapy, radiotherapy, or 'immunogenic' chemotherapy by leveragin

195 ontrol group, investigating hypofractionated radiotherapy, or including mostly nasopharyngeal carcino

196 Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive orga

197 ded management plans for treatment (surgery, radiotherapy, or systemic therapy) within 90 d for lung

198 the rationale of blocking TRIP12 to improve radiotherapy outcomes.

199 explain the superiority of hyperfractionated radiotherapy over other altered fractionation radiothera

200 sone for the prophylaxis of pain flare after radiotherapy, patients were accrued from 23 Canadian cen

201 tinal toxicity in patients undergoing pelvic radiotherapy.Patients were randomly assigned to low-fibe

202 y included patients treated with proton beam radiotherapy (PBR) for a small CM.

203 the patient's computed tomography images and radiotherapy plan.

204 patients with nonmetastatic disease with no radiotherapy planned and for patients with metastatic di

205 F risk for patients before treatment, during radiotherapy planning, and during follow-up.

206 oor prognosis for survival and is central to radiotherapy planning.

207 ast cancer with computed tomography-assisted radiotherapy planning.

208 For radiotherapy plans, agreement ranged from 80.0% to 84.4%

209 External-beam radiotherapy plays a critical role in the treatment of m

210 In each model, external beam radiotherapy plus venetoclax synergistically increased m

211 photodynamic therapy, photothermal therapy, radiotherapy, protected delivery of bioactive moieties,

212 Purpose Radiotherapy reduces the absolute risk of breast cancer

213 ction can be omitted or replaced by axillary radiotherapy, reducing morbidity.

214 adiotherapy over other altered fractionation radiotherapy regimens and to assess the benefit of alter

215 ever, overall survival in patients receiving radiotherapy remained very good, with the 5-year and 10-

216 Clinical Question: Is up-front whole-brain radiotherapy required to treat multiple brain metastases

217 ts may alter MDM2 expression and thus affect radiotherapy response and prognosis of squamous cell car

218 ce to follow a high-fiber diet during pelvic radiotherapy resulted in reduced gastrointestinal toxici

219 but smoking cessation substantially reduces radiotherapy risk.

220 Purpose To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation surgery in d

221 ecutive female patients with BC treated with radiotherapy (RT) after breast-conserving surgery.

222 The use of a radiotherapy (RT) boost to the tumor bed after whole-bre

223 Adjuvant radiotherapy (RT) in breast cancer (BC) is often used to

224 Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections

225 Preoperative radiotherapy (RT) is a mainstay in the management of rec

226 state cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks.

227 kelihood of a local relapse, the addition of radiotherapy (RT) to limb-sparing surgery may result in

228 r receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard chemoradiotherapy in locor

229 ed patients with stage III disease receiving radiotherapy (RT) with carboplatin-paclitaxel or cisplat

230 ission tomography (PET) imaging and internal radiotherapy (RT).

231 uideline on treatment with stereotactic body radiotherapy (SBRT) for patients with early-stage non-sm

232 tage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial.

233 zed clinical trial of stereotactic conformal radiotherapy (SCRT) compared with conventional radiother

234 nd adjuvant temozolomide to hypofractionated radiotherapy seems to be safe and efficacious without im

235 valence, the implication is that twice-daily radiotherapy should continue to be considered the standa

236 breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases).

237 ntional radiotherapy, with hyperfractionated radiotherapy showing the greatest benefit.

238 Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy

239 a-camera with (90)Y after selective internal radiotherapy (SIRT) may allow for verification of treatm

240 lineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usual

241 ain management-analgesia, adjunct therapies, radiotherapy, surgery, systemic anticancer therapy, and

242 Cs (including those recurrent after surgery, radiotherapy, systemic chemotherapy, or topical chemothe

243 iasm for clinical use of advanced MRI-guided radiotherapy systems.

244 This simple radiotherapy technique is implementable in radiotherapy

245 Radiotherapy techniques for photon therapy have also evo

246 ential role of modern imaging and innovative radiotherapy techniques in minimisation of neurocognitiv

247 lication of stereotactic and other conformal radiotherapy techniques in treating brain tumors is larg

248 These data emphasize the importance of radiotherapy techniques that limit MCRD during breast ca

249 nger in patients who previously received any radiotherapy than in patients without previous radiother

250 nger in patients who previously received any radiotherapy than in patients without previous radiother

251 ed individualized counseling at the start of radiotherapy to achieve these targets.

252 ty of these particles and their use in chemo-radiotherapy to effectively reduce lung tumors.

253 Using radiotherapy to enhance the targeting of CpG to tumors m

254 The mean interval from radiotherapy to HF was 5.8+/-3.4 years.

255 vidence demonstrates that adding neoadjuvant radiotherapy to surgery offers better local control in t

256 imiting radiation dermatitis associated with radiotherapy, to cutaneous radiation syndrome, a frequen

257 In patients assessed for radiotherapy toxicity, was no difference in grade 3-4 oe

258 were also strongly predictive of outcome in radiotherapy-treated patients across multiple independen

259 patients to groups, stratifying patients by radiotherapy treatment centre.

260 rmation of interest that may be relevant for radiotherapy treatment planning.

261 should be done relative to PMRT and whether radiotherapy treatment should be directed towards the ti

262 occurred more often in patients with radical radiotherapy treatment, positive (68)Ga-PSMA scan result

263 gnosis, approaches to surgery, chemotherapy, radiotherapy, treatment of recurrence, palliative care,

264 evious study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic

265 cally advanced cSCC who declined surgery and radiotherapy underwent treatment with pembrolizumab, an

266 sis, prior chemotherapy, prior external-beam radiotherapy, uptake on the [(111)In-DTPA(0)]octreotide

267 Areas with more radiotherapy use for DCIS had increased use of mastectom

268 Residence in an HSA characterized by greater radiotherapy use for DCIS increased the likelihood of re

269 ervice areas (HSAs) into 3 clusters based on radiotherapy use.

270 pread use of techniques such as image-guided radiotherapy, volumetric modulated arc therapy, helical

271 Comparison 1 (conventional fractionation radiotherapy vs altered fractionation radiotherapy) incl

272 among patients not receiving previous pelvic radiotherapy was 24.5 months versus 16.8 months (0.64 [0

273 Altered fractionation radiotherapy was associated with a significant benefit o

274 (nonmetastatic); prostate (+/- pelvic node) radiotherapy was encouraged for men without metastases.

275 Local radiotherapy was mandated for patients with node-negativ

276 In 24 cases, radiotherapy was planned to a clinical target volume con

277 change in score between the start and end of radiotherapy was smaller in the high-fiber group (mean +

278 Whole brain radiotherapy (WBRT) is the standard of care to improve i

279 Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor recepto

280 The involvement of surgery and radiotherapy were among the most significant factors ass

281 AML de novo or secondary to chemotherapy or radiotherapy were enrolled in the study.

282 First line treatment is radiotherapy, which many patients often forego to avoid

283 lue predicts for high therapeutic effect for radiotherapy; which we postulate would relate to clinica

284 intestinal tract from deleterious effects of radiotherapy will significantly improve patient quality

285 To investigate QOL at days 10 and 42 after radiotherapy with a bone metastases-specific QOL tool.

286 We assessed the use of radiotherapy with concurrent and adjuvant temozolomide i

287 Recommendations Partial-brain fractionated radiotherapy with concurrent and adjuvant temozolomide i

288 mozolomide given on days 1-5); or to receive radiotherapy with concurrent temozolomide 75 mg/m(2) per

289 days apart, followed by intensity-modulated radiotherapy with daily image guidance plus 30 mg/m(2) p

290 ain reduction and better QOL at day 10 after radiotherapy with further improvements in QOL at day 42

291 To administer radiotherapy with immunotherapy has been shown to improv

292 metastases patients receiving involved-sites radiotherapy with low dose schemas.

293 HNSCC from a phase 3 trial of cisplatin plus radiotherapy with or without cetuximab (NRG Oncology RTO

294 Twenty-five studies reported results using radiotherapy with or without chemotherapy or surgery.

295 For salvage laryngectomy after radiotherapy with or without chemotherapy, reconstructio

296 and provide a rationale for combining chemo/radiotherapy with TIMP1 inhibitors in PDAC.

297 t seen in patients who did not have previous radiotherapy, with an acceptable safety profile.

298 se 2 dose of veliparib plus capecitabine and radiotherapy, with an exposure-adjusted continual reasse

299 ion-free survival compared with conventional radiotherapy, with hyperfractionated radiotherapy showin

300 was defined as chemotherapy, with or without radiotherapy, within 90 days of surgery.